Literature DB >> 12410095

Scleroderma overlap syndromes.

Janet E Pope1.   

Abstract

Scleroderma is a connective tissue disease that causes fibrosis and vascular abnormalities, but that also has an autoimmune component. Many patients with scleroderma have a positive antinuclear antibody, and there can be family histories of other connective tissue diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Some patients have features of scleroderma and other autoimmune conditions. This article will review recent literature to help in the understanding of scleroderma with overlap features. Recent reports of scleroderma overlap with rheumatoid arthritis suggest distinct features of diffuse scleroderma with positive Scl-70, pulmonary fibrosis, and later seropositive erosive rheumatoid arthritis. SLE rarely occurs with scleroderma. Sjögren syndrome symptoms are common in scleroderma. In primary Sjögren syndrome, anticentromere antibody positive patients have more Raynaud phenomenon. Antibodies that occur in scleroderma that are thought to be specific are present in other connective tissue diseases. For instance, Scl-70 antibody is reported in as many as 35% of patients with scleroderma but can be present in 25% of patients with SLE. Myositis or myopathy can be features of scleroderma. Scleroderma overlap with polymyositis is frequently anti-PM Scl antibody positive, whereas anti-Jo-1 does not normally occur in the overlap of scleroderma and polymyositis but is usually exclusively positive in polymyositis with arthritis and alveolitis. A better prognosis is found with PM Scl antibody in myositis. Vasculitis is not a typical feature of scleroderma, but has been reported. Eosinophilic fasciitis is rare, and the onset could be associated with simvastatin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410095     DOI: 10.1097/00002281-200211000-00013

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  10 in total

1.  A case of MCTD overlapped by Takayasu's arteritis, presenting Raynaud's phenomenon as the initial manifestation of both diseases.

Authors:  Mie Jin Lim; Seong Ryul Kwon; Sang Gu Kim; Won Park
Journal:  Rheumatol Int       Date:  2008-10-11       Impact factor: 2.631

Review 2.  [Is bioptic assurance reasonable in patients with Sjögren's syndrome? From focus score to diagnosing vasculitides].

Authors:  V Krenn; M Jakobs; J Kriegsmann; M G Krukemeyer; A Rieger
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

3.  Multiple avascular necrosis in a patient with systemic lupus erythematosus/systemic sclerosis overlap syndrome.

Authors:  Javier Alberto Cavallasca; Hugo Armando Laborde; Mariela Beatriz Araujo; Gustavo Guillermo Nasswetter
Journal:  Clin Rheumatol       Date:  2005-01-20       Impact factor: 2.980

4.  Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation.

Authors:  Claudio Corallo; Maurizio Cutolo; Nila Volpi; Daniela Franci; Margherita Aglianò; Antonio Montella; Chiara Chirico; Stefano Gonnelli; Ranuccio Nuti; Nicola Giordano
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-03       Impact factor: 5.346

5.  Leveraging Google Trends to investigate the global public interest in rheumatoid arthritis.

Authors:  Guo-Cui Wu; Sha-Sha Tao; Chan-Na Zhao; Yan-Mei Mao; Qian Wu; Yi-Lin Dan; Hai-Feng Pan
Journal:  Rheumatol Int       Date:  2019-04-06       Impact factor: 2.631

6.  Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.

Authors:  Anders Carlsson; Dirk M Wuttge; Johan Ingvarsson; Anders A Bengtsson; Gunnar Sturfelt; Carl A K Borrebaeck; Christer Wingren
Journal:  Mol Cell Proteomics       Date:  2011-02-24       Impact factor: 5.911

Review 7.  Antibodies in scleroderma: direct pathogenicity and phenotypic associations.

Authors:  Lorinda Chung; Paul J Utz
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

8.  Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.

Authors:  Rudolf Mierau; Pia Moinzadeh; Gabriela Riemekasten; Inga Melchers; Michael Meurer; Frank Reichenberger; Michael Buslau; Margitta Worm; Norbert Blank; Rüdiger Hein; Ulf Müller-Ladner; Annegret Kuhn; Cord Sunderkötter; Aaron Juche; Christiane Pfeiffer; Christoph Fiehn; Michael Sticherling; Percy Lehmann; Rudolf Stadler; Eckhard Schulze-Lohoff; Cornelia Seitz; Ivan Foeldvari; Thomas Krieg; Ekkehard Genth; Nicolas Hunzelmann
Journal:  Arthritis Res Ther       Date:  2011-10-21       Impact factor: 5.156

Review 9.  Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options.

Authors:  Christian Michael Hedrich; Hildegard Zappel; Simon Straub; Martin W Laass; Kathrin Wieczorek; Gabriele Hahn; Georg Heubner; Manfred Gahr
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 3.650

10.  High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy.

Authors:  Nicolas Hunzelmann; Pia Moinzadeh; Ekkehard Genth; Thomas Krieg; Walter Lehmacher; Inga Melchers; Michael Meurer; Ulf Müller-Ladner; Thorsten M Olski; Christiane Pfeiffer; Gabriela Riemekasten; Eckhard Schulze-Lohoff; Cord Sunderkoetter; Manfred Weber
Journal:  Arthritis Res Ther       Date:  2009-03-04       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.